Vizsgálati helyszín
PV Medical Services s.r.o.
Zlín, Zlín 760 01, CsehországEU-13 felzárkózó országMég nincs intézményhez kötve
- 13futó vizsgálat
- 8lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 21 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis14 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis1 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz10 vizsgálat
- Lezárult8 vizsgálat
- Még nem toboroz2 vizsgálat
- Toboroz1 vizsgálat
- Fő szponzor
- MoonLake Immunotherapeutics AG3 vizsgálat
- Sun Pharmaceutical Industries Limited3 vizsgálat
- AbbVie2 vizsgálat
- Janssen Research & Development, LLC2 vizsgálat
- Takeda2 vizsgálat
- és még 9
Futó vizsgálatok
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Takeda· Forrás
Még nem toboroz
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
2025-524005-32-00· 2. fázis· Elevara Medicines Limited· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis
2024-519291-11-00· 2. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT06972446· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462· 2. fázis· Immunovant Sciences GmbH· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Fut, nem toboroz
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308· 3. fázis· AbbVie· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
2024-514981-37-00· 2. fázis· Synact Pharma ApS· Forrás
Lezárult
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· 3. fázis· Dr Reddy's Laboratories Limited· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228· 3. fázis· UCB Biopharma SRL· Forrás
Lezárult
Tofacitinib in early active axial spondyloarthritis: a prospective, randomized, double-blind, placebo-controlled multicentre study - FASTLANE
2023-505050-18-00· 4. fázis· Charite Universitaetsmedizin Berlin KöR· Forrás
Lezárult
A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is
2022-501362-22-00· 2/3. fázis· Acelyrin Inc.· Forrás
Lezárult
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
2024-512142-42-00· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Fut, nem toboroz
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· 3. fázis· Bristol-Myers Squibb· Forrás
Lezárult
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Hibát jelzek